News15/Ratings0
Price$5.38-1.33 (-19.86%)
2026-03-042026-06-05
News · 26 weeks15-60%
2025-12-142026-06-07
Mix1590d
- SEC Filings9(60%)
- Other4(27%)
- Insider2(13%)
Latest news
15 items- SECNexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- PRNexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical DevelopmentNess Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound. This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that the Company's propr
- SECSEC Form 10-Q filed by Nexentis Technologies Inc.10-Q - Nexentis Technologies Inc. (0001789192) (Filer)
- PRNexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery MilestoneMITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit
- PRNexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE™Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS), ("Nexentis" or the "Company"), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™. MITOLINE™ is MitoCareX's proprietary sequence analysis and alignment algorithm designed to prepare mitochondrial carrier proteins of the SLC25 family for reliable 3D homology modeling and was designed to overcome
- SECNexentis Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- SECSEC Form EFFECT filed by Nexentis Technologies Inc.EFFECT - Nexentis Technologies Inc. (0001789192) (Filer)
- SECSEC Form S-3 filed by Nexentis Technologies Inc.S-3 - Nexentis Technologies Inc. (0001789192) (Filer)
- SECNexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- SECSEC Form 10-K filed by Nexentis Technologies Inc.10-K - Nexentis Technologies Inc. (0001789192) (Filer)
- INSIDERSEC Form 4 filed by Lee Eun Young4 - Nexentis Technologies Inc. (0001789192) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lee Eun Young3 - Nexentis Technologies Inc. (0001789192) (Issuer)
- SECNexentis Technologies Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Nexentis Technologies Inc. (0001789192) (Filer)
- PRNexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech PlatformVisit Nexentis at: www.nexentistech.com Neve Yarak, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS), ("Nexentis" and the "Company"), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, is proud to announce the launch of its new corporate website at www.nexentistech.com. This digital milestone follows the company's recent rebranding from N2OFF, Inc., and underscores its commitment to advancing mitochondrial biology for breakthroughs in precision oncology and inflammatory metabolic diseases. The newly launched website serves as a comprehensive hub for stakeholders, including investors,
- SECSEC Form DEF 14A filed by Nexentis Technologies Inc.DEF 14A - Nexentis Technologies Inc. (0001789192) (Filer)
NXTS FAQ
4 questionsWhere does NXTS stock trade?
Nexentis Technologies Inc. (NXTS) is listed on NASDAQ.What sector and industry is NXTS in?
Nexentis Technologies Inc. operates in the Industrials sector, Agricultural Chemicals industry.What companies are similar to NXTS?
Notable peers in the same industry include NTR (Nutrien Ltd.), CF (CF Industries Holdings Inc.), ICL (ICL Group Ltd.), MOS (Mosaic Company), SMG (Scotts Miracle-Gro Company). Compare NXTS side-by-side with any of them on Quantisnow.How can I track NXTS on Quantisnow?
Quantisnow aggregates Nexentis Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXTS to receive live email and push alerts on every new disclosure.